Therapeutic goal and molecular design Kalytera is investigating two compounds to assess their potential ability to improve bone fracture healing, including cannabidiol (“CBD”), a natural non-psychoactive cannabis constituent, and KAL436/9, a synthetic derivative of CBD that has been structurally modified to enhance solubility in water to improve potency.
Current pharmacology studies Kalytera is collaborating with Dr. Yankel Gabet, the Director of the Bone Research Laboratory at Tel Aviv University. In 2015 Dr. Gabet published a study showing that cannabidiol (“CBD”) increased collagen cross-linking and stabilization in rat femurs, increasing the maximal load and work-to-failure, but not the stiffness.
Unmet need Approximately one-third of all tibial and femoral shaft fractures have delayed rates of healing or non-healing. Patients with delayed union or non-union can expect poorer outcomes, including increased pain, loss of function, loss of quality of life, and delay in return to work. There are currently limited treatment options available for improving the rate of bone healing and bone fracture repair. Bone morphogenetic proteins (“BMPs”) and anabolic agents, including Teriparatide (“TPD”), are costly and may lack desired efficacy; improved therapeutic options are desired.